No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Chizl’ – Developed for Individuals Seeking Fast & Effective Pain Relief On-the-Go

Editor: What To Know

  • “With faster and more effective pain relief for the whole body being our main focus, it only made sense to develop a product that allows users to improve mobility and achieve relief whenever and wherever they need it the most.
  • The launch follows the official release of Mobility Wall’s game-changing vertical foam roller collection in September 2021, including Mobility Wall Smooth Roller and Mobility Wall Pro Series.
  • Featuring unmatched portability, The Chizl provides the benefits of Mobility Wall’s Smooth Roller and Pro Series in a compact yet powerful, sleek design.

The Chizl, (handheld) was developed for those seeking fast and effective pain relief on-the-go. The Chizl offers users full control of their manual treatment without the hassle of cords, batteries, setup, and noise.

The launch follows the official release of Mobility Wall’s game-changing vertical foam roller collection in September 2021, including Mobility Wall Smooth Roller and Mobility Wall Pro Series.

“Mobility Wall’s vertical roller collection was created with every kind of user in mind,” says Mobility Wall Inventor & Co-Founder, Chris DiVecchio. “With faster and more effective pain relief for the whole body being our main focus, it only made sense to develop a product that allows users to improve mobility and achieve relief whenever and wherever they need it the most.”

Featuring unmatched portability, The Chizl provides the benefits of Mobility Wall’s Smooth Roller and Pro Series in a compact yet powerful, sleek design.

The handheld product’s attachments include “The Wedge,” to improve blood flow and neurological connectivity using short and long tissue glides, “The Thumb,” a small, smooth, and incredibly strong tool made to dig into knots, and “The Cone,” which uses a fine point tip to reach areas like the hands and feet as well as separate muscle fibers that often get stuck together like the quads and calves.

The Chizl retails for $49 ($39 when pre-ordering). To pre-order The Chizl, which is expected to ship early 2022 visit here.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy